Pfizer Outlines Postacquisition Manufacturing Strategy

Following its $68-billion acquisition of Wyeth, Pfizer is integrating its manufacturing and outsourcing activities (Podcast).
Mar 03, 2010
By PharmTech Editors

Following its $68-billion acquisition of Wyeth (Madison, NJ), Pfizer (New York) is integrating its manufacturing and outsourcing activities. In a joint podcast with its sister publication BioPharm International, Pharmaceutical Technology discusses Pfizer's plans for manufacturing integration with Tony Maddaluna, senior vice-president of strategy and supply-network transformation at Pfizer Global Manufacturing. The podcast is moderated by Laura Bush, editor-in-chief of BioPharm International